Drug Search Results
More Filters [+]

Piclozotan

Alternative Names: piclozotan
Latest Update: 2021-03-11
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: 5-HT1A Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Piclozotan

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Ischemic Stroke|Stroke|Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ASBI-501

P2

Completed

Parkinson's Disease

2008-07-17

2004-002437-39

P2

Terminated

Stroke

2006-10-24

SPI-103

P2

Terminated

Ischemic Stroke

2006-10-01

Recent News Events

Date

Type

Title